Decheng Capital LLC Reduces Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

Decheng Capital LLC trimmed its stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 28.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,767 shares of the company's stock after selling 20,000 shares during the period. Vera Therapeutics accounts for approximately 0.5% of Decheng Capital LLC's holdings, making the stock its 24th largest position. Decheng Capital LLC owned about 0.08% of Vera Therapeutics worth $2,105,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of VERA. Huntington National Bank purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at about $26,000. AlphaQuest LLC purchased a new position in shares of Vera Therapeutics during the fourth quarter valued at about $34,000. KBC Group NV lifted its holdings in shares of Vera Therapeutics by 127.2% in the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after acquiring an additional 1,387 shares during the last quarter. Summit Investment Advisors Inc. raised its position in Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock valued at $196,000 after purchasing an additional 639 shares during the period. Finally, Moors & Cabot Inc. bought a new stake in shares of Vera Therapeutics in the 4th quarter valued at approximately $220,000. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA traded down $0.39 during mid-day trading on Thursday, reaching $22.98. The company's stock had a trading volume of 317,099 shares, compared to its average volume of 895,092. The stock has a 50-day moving average of $24.93 and a two-hundred day moving average of $35.56. The stock has a market capitalization of $1.46 billion, a P/E ratio of -8.80 and a beta of 1.28. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

VERA has been the topic of several analyst reports. Guggenheim boosted their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a "buy" rating in a research report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price objective on the stock. JPMorgan Chase & Co. cut their price objective on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. Finally, Wolfe Research initiated coverage on Vera Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, Vera Therapeutics presently has a consensus rating of "Buy" and an average price target of $64.67.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.